STARD4: A Potential Drug Target and Biomarker for Star-Related Lipid Transfer in Cancer

Target Name: STARD4

NCBI ID: G134429

STARD4

STARD4: A Potential Drug Target and Biomarker for Star-Related Lipid Transfer in Cancer

Star-related lipid transfer (SRLT) is a process by which free fatty acids (FFAs) are transferred from the mitochondria to the cytosol, where they can be used for energy by the cytosolative microenvironment (CM). This process is critical for maintaining cellular energy homeostasis and has been implicated in various diseases, including cancer. The STARD4 gene, located on chromosome 16p13.1, has been identified as a gene that is involved in SRLT. In this article, we will discuss the STARD4 gene, its function in SRLT, and its potential as a drug target or biomarker for cancer.

Functional Analysis of the STARD4 Gene

The STARD4 gene encodes a protein named STARD4, which is a member of the Lipid Transfer Proteins (LTPs) family. As mentioned earlier, LTPs are a group of transmembrane proteins that play a crucial role in intracellular lipid transport and metabolism. STARD4 is characterized by a N-terminal transmembrane domain, a catalytic domain, and a C-terminal T-loop region.

The N-terminal transmembrane domain of STARD4 is responsible for the protein's intracellular localization and its ability to interact with various cellular components. This domain has been shown to interact with various cellular signaling pathways, including the TGF-β and Wnt signaling pathways. The catalytic domain of STARD4 is responsible for its catalytic activity, which is essential for the efficient transfer of free fatty acids from the mitochondria to the cytosol.

The C-terminal T-loop region of STARD4 is a critical region for protein stability and functions as a binding site for various intracellular signaling pathways. This region has been shown to interact with various proteins, including tyrosine kinases, poly(ADP-ribose) polymerase (PARP), and 5-lipoxygenase (5-LO).

Potential Drug Target or Biomarker

The STARD4 gene has been implicated in various diseases, including cancer. Several studies have shown that STARD4 is involved in the regulation of cellular processes that are crucial for cancer progression, such as cell adhesion, migration, and angiogenesis.

One of the potential drug targets for STARD4 is the inhibition of its catalytic activity. This can be achieved by inhibiting the activity of the STARD4 protein, which would reduce the amount of free fatty acids that are transferred from the mitochondria to the cytosol. This would result in a decrease in cellular energy homeostasis and a shift in cellular metabolism towards a state of energy starvation, which can lead to the inhibition of cancer cell growth and progression.

Another potential biomarker for STARD4 is the measurement of the amount of free fatty acids (FFAs) in the cytosol of cancer cells. As mentioned earlier, STARD4 is responsible for the efficient transfer of free fatty acids from the mitochondria to the cytosol. Therefore, the amount of FFA in the cytosol can be used as an indicator of STARD4 function and its potential as a drug target or biomarker for cancer.

Conclusion

In conclusion, the STARD4 gene has been identified as a gene that is involved in SRLT and has been shown to play a crucial role in the regulation of cellular processes that are crucial for cancer progression. The inhibition of STARD4's catalytic activity or the measurement of the amount of free fatty acids in the cytosol of cancer cells can be potential drug targets or biomarkers for cancer. Further research is needed to

Protein Name: StAR Related Lipid Transfer Domain Containing 4

Functions: Involved in the intracellular transport of cholesterol. Binds cholesterol or other sterols

The "STARD4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STARD4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets